Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 2/20 | 0.43 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.43 |
| ▸ | MYC | P01106 | 1/20 | 0.43 |
| ▸ | MAX | P61244 | 1/20 | 0.43 |
| ▸ | GPR132 | Q9UNW8 | 4/20 | 0.43 |
| ▸ | ALB | P02768 | 1/20 | 0.42 |
| ▸ | IL2 | P60568 | 1/20 | 0.42 |
| ▸ | GRN | P28799 | 1/20 | 0.41 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.41 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.41 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5516526 | 1.00 | HDAC1 (0.45) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL5514129 | 0.85 | HDAC1 (0.44) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL5514133 | 0.85 | HDAC1 (0.44) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL28088739 | 0.85 | GPR132 (0.52) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL26263203 | 0.85 | GPR132 (0.52) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL26264263 | 0.82 | CA2 (0.51) | HDAC1HDAC2MTORTP53BP1MYC | |
| SCHEMBL17680606 | 0.78 | NPSR1 (0.59) | HDAC1HDAC2GRM5MTORTP53BP1 | |
| SCHEMBL5520008 | 0.78 | CTSL (0.57) | — | |
| SCHEMBL5520013 | 0.78 | CTSL (0.57) | — | |
| SCHEMBL5582056 | 0.77 | CTSB (0.39) | HDAC1HDAC2GRM5MTORTP53BP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | QUEST DIAGNOSTICS INVESTMENTS LLC | 2007-04-19 | — | — | US | disclosed |
| EP-1716158-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | Schering Aktiengesellschaft (DE) | 2006-11-02 | — | — | EP | disclosed |
| WO-2005074904-A2 | SILINANE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070088001-A1 | Silinane compounds as cysteine protease inhibitors | CTSV, CTSB, CTSS | HDAC1 558/4885HDAC2 680/4885GRM5 4265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.